mitoxantrone has been researched along with Mucositis, Oral in 12 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A phase II study was performed at the MTD of paclitaxel in patients with doxorubicin/mitoxantrone-refractory metastatic breast cancer." | 9.07 | Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. ( Bates, S; Berg, SL; Bryant, G; Fojo, A; Goldspiel, BR; Herdt, J; O'Shaughnessy, J; Steinberg, SM; Wilson, WH; Wittes, RE, 1994) |
| "Seventeen patients with relapsed or refractory acute nonlymphocytic leukemia were treated with 14 mg/m2 of mitoxantrone given in a 30-minute infusion daily for three days." | 7.67 | Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. ( Ball, ED; Cornell, CJ; Cornwell, GG; McIntyre, OR; Mills, LE; O'Donnell, JF; Vredenburgh, JJ, 1988) |
| "Twenty-three patients with advanced breast cancer were treated with the combination of mitoxantrone and doxorubicin." | 7.67 | Combined mitoxantrone plus doxorubicin in the treatment of breast cancer. ( Lefebvre, BM; Maroun, JA; Perrault, DJ; Stewart, DJ, 1987) |
| "Results of first-line mitoxantrone chemotherapy for advanced breast cancer are presented." | 7.67 | First-line mitoxantrone chemotherapy for advanced breast cancer. ( Paterson, AH; Wilson, KS, 1986) |
| "Mitoxantrone was evaluated in a multi-institution trial to define the effective dose for treating acute leukemia, to evaluate its toxicity, and to assess the induction rates for the different types of acute leukemia." | 7.67 | Phase I-II trial of mitoxantrone in acute leukemia. ( Arlin, ZA; Armentrout, S; Cassileth, P; Coleman, M; Daghestani, A; Dukart, G; Gams, R; Schoch, I; Silver, R, 1985) |
| " A phase II study was performed at the MTD of paclitaxel in patients with doxorubicin/mitoxantrone-refractory metastatic breast cancer." | 5.07 | Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. ( Bates, S; Berg, SL; Bryant, G; Fojo, A; Goldspiel, BR; Herdt, J; O'Shaughnessy, J; Steinberg, SM; Wilson, WH; Wittes, RE, 1994) |
| "Seventeen patients with relapsed or refractory acute nonlymphocytic leukemia were treated with 14 mg/m2 of mitoxantrone given in a 30-minute infusion daily for three days." | 3.67 | Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. ( Ball, ED; Cornell, CJ; Cornwell, GG; McIntyre, OR; Mills, LE; O'Donnell, JF; Vredenburgh, JJ, 1988) |
| "Twenty-three patients with advanced breast cancer were treated with the combination of mitoxantrone and doxorubicin." | 3.67 | Combined mitoxantrone plus doxorubicin in the treatment of breast cancer. ( Lefebvre, BM; Maroun, JA; Perrault, DJ; Stewart, DJ, 1987) |
| "Results of first-line mitoxantrone chemotherapy for advanced breast cancer are presented." | 3.67 | First-line mitoxantrone chemotherapy for advanced breast cancer. ( Paterson, AH; Wilson, KS, 1986) |
| "Mitoxantrone was evaluated in a multi-institution trial to define the effective dose for treating acute leukemia, to evaluate its toxicity, and to assess the induction rates for the different types of acute leukemia." | 3.67 | Phase I-II trial of mitoxantrone in acute leukemia. ( Arlin, ZA; Armentrout, S; Cassileth, P; Coleman, M; Daghestani, A; Dukart, G; Gams, R; Schoch, I; Silver, R, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Vliet, MJ | 1 |
| Tissing, WJ | 1 |
| Rings, EH | 1 |
| Koetse, HA | 1 |
| Stellaard, F | 1 |
| Kamps, WA | 1 |
| de Bont, ES | 1 |
| Apostolidou, E | 1 |
| Estey, E | 1 |
| Cortes, J | 1 |
| Garcia-Manero, G | 1 |
| Faderl, S | 1 |
| Thomas, D | 1 |
| Tsimberidou, A | 1 |
| Kantarjian, H | 1 |
| Giles, FJ | 1 |
| Thomas, X | 1 |
| Elhamri, M | 1 |
| Chelghoum, Y | 1 |
| Reman, O | 1 |
| Arnaud, P | 1 |
| Raffoux, E | 1 |
| Le, QH | 1 |
| Tavernier, E | 1 |
| Dombret, H | 1 |
| Michallet, M | 1 |
| Wilson, WH | 1 |
| Berg, SL | 1 |
| Bryant, G | 1 |
| Wittes, RE | 1 |
| Bates, S | 1 |
| Fojo, A | 1 |
| Steinberg, SM | 1 |
| Goldspiel, BR | 1 |
| Herdt, J | 1 |
| O'Shaughnessy, J | 1 |
| Feldman, EJ | 1 |
| Seiter, K | 1 |
| Traganos, F | 1 |
| Darzynkiewicz, Z | 1 |
| Goff, H | 1 |
| Pozzuoli, M | 1 |
| Baskind, P | 1 |
| Santos, S | 1 |
| Ahmed, T | 1 |
| Thurnher, D | 1 |
| Kornfehl, J | 1 |
| Burian, M | 1 |
| Gedlicka, C | 1 |
| Selzer, E | 1 |
| Quint, C | 1 |
| Neuchrist, C | 1 |
| Kornek, GV | 1 |
| Gherlinzoni, F | 1 |
| Guglielmi, C | 1 |
| Mazza, P | 1 |
| Amadori, S | 1 |
| Mandelli, F | 1 |
| Tura, S | 1 |
| Kreisle, WH | 1 |
| Alberts, DS | 1 |
| List, AF | 1 |
| McCloskey, T | 1 |
| Plezia, P | 1 |
| Peng, YM | 1 |
| George, M | 1 |
| Vredenburgh, JJ | 1 |
| McIntyre, OR | 1 |
| Cornwell, GG | 1 |
| Ball, ED | 1 |
| Cornell, CJ | 1 |
| Mills, LE | 1 |
| O'Donnell, JF | 1 |
| Stewart, DJ | 1 |
| Perrault, DJ | 1 |
| Maroun, JA | 1 |
| Lefebvre, BM | 1 |
| Wilson, KS | 1 |
| Paterson, AH | 1 |
| Arlin, ZA | 1 |
| Silver, R | 1 |
| Cassileth, P | 1 |
| Armentrout, S | 1 |
| Gams, R | 1 |
| Daghestani, A | 1 |
| Coleman, M | 1 |
| Schoch, I | 1 |
| Dukart, G | 1 |
8 trials available for mitoxantrone and Mucositis, Oral
| Article | Year |
|---|---|
Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Ca | 2009 |
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Human | 2003 |
Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 2005 |
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
Topics: Adult; Aged; Agranulocytosis; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Resi | 1994 |
Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia.
Topics: Actuarial Analysis; Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 2000 |
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
Phase III comparative trial (m-BACOD v m-BNCOD) in the treatment of stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; | 1990 |
A phase I trial of 14-day continuous intravenous infusion mitoxantrone.
Topics: Adult; Aged; Diarrhea; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Infusions, Intrav | 1991 |
4 other studies available for mitoxantrone and Mucositis, Oral
| Article | Year |
|---|---|
Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia.
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Drug Evaluation; Drug Resistance; Hema | 1988 |
Combined mitoxantrone plus doxorubicin in the treatment of breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Breast | 1987 |
First-line mitoxantrone chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1986 |
Phase I-II trial of mitoxantrone in acute leukemia.
Topics: Acute Disease; Adult; Aged; Anthraquinones; Drug Evaluation; Female; Heart; Humans; Leukemia; Leukem | 1985 |